anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
A therapeutic device has a bridge portion adapted for releasable adherence to a patch of skin so as to lift the patch of skin above a sensitive underlying treatment site in reducing 5 discomfort or pain associated with tissue compression at the treatment site. The bridge portion is elevated above the treatment site with an exposed adhesive facing the patch of skin to be lifted and/or stretched outwardly. With the application of pressure to elastically deform the device from its original neutral configuration, the bridge portion is brought into contact with the patch of skin, adhering the skin to the adhesive. When the pressure is removed, the LO device rebounds and generally reassumes its original configuration with the bridge portion lifting the attached patch of skin. !0 !5 220 208.&#39; /oo!:/,102 zIo.0 204 z
PURPOSE:To provide the titled cosmetic composed of a pigment having specific diameter, sodium alginate, etc. and sodium ethylene-diaminetetraacetate, etc., having low viscosity and excellent lining and coating capability, and extrudable easily from the pen without causing clogging of the pen. CONSTITUTION:The objective cosmetic is composed of (A) a pigment having particle diameter of &lt;=1mu, (B) sodium alginate, carboxymethylcellulose sodium salt, sodium polyacrylate, sodium, ammonium or N-alkanolamine salt, etc. of shellac or their mixture having strong property of protective colloid and effective as a dispersant to prevent the precipitation of the pigment, and (C) sodium, trisodium or disodium salt of ethylenediaminetetraacetic acid as an insolubilizing agent of a porous thermoplastic resin. The viscosity of the cosmetic is 1.5-50cp. The liquid cosmetic is filled in a pen-type cosmetic container such as eyeliner having a pen especially made of a urethane resin.
The present invention provides a peptide comprising 1) a B-cell epitope, 2) a protective part, and 3) a Th epitope. The B-cell epitope and the protective part combine to form a Th-epitope-protective epitope. The peptide is characterized in that the protective part is linked to the N&#39;-terminus and C&#39;-terminus of the Th epitope, and when injected into a body of a subject, an antibody that specifically binds to an intentionally designed B-cell epitope is uniformly induced. In addition, since the peptide contains a small number of B-cell and Th epitopes, the prsesent invention has advantages of easy production and economical efficiency. The peptide may be used as an immunotherapeutic agent according to its characteristics. Accordingly, a peptide designed to be used as an immunotherapeutic agent for obesity and a pharmaceutical composition thereof are provided.
A computer that determines at least an anatomic feature of a left atrial appendage (LAA) is described. During operation, the computer generates a 3D image associated with an individual&#39;s heart. This 3D image may present a view along a perpendicular direction to an opening of the LAA. Then, the computer may receive information specifying a set of reference locations. For example, the set of reference locations may include: a location on a circumflex artery, a location between a superior portion of the LAA and a left pulmonary vein, and/or a location on a superior wall of the LAA and distal to trabeculae carneae. Next, the computer automatically determines, based, at least in part, on the set of reference locations, at least the anatomical feature of the LAA, which is associated with the opening of the LAA and a size of a device used in an LAA closure (LAAC) procedure.
The invention concerns a process for diagnosing Alzheimer&#39;s disease and diseases of similar aetiology and pharmaceutical agents for use in therapy. The fields of application are medicine and pharmaceuticals. The basis of the invention is the surprising finding that a causative factor in Alzheimer&#39;s disease is the pathological production of activated autospecific T-lymphocytes in peripheral blood. The activated T-lymphocytes pass through the blood-brain barrier, succumb to apoptosis on interacting with microglia cells and, with the microglia activation, trigger the characteristic neurotoxic inflammation process. The process according to the invention involves the use of a sample of peripheral blood with which Alzheimer&#39;s disease is diagnosed from the high proportion of apoptosis-affected (dying) mononuclear cells, or from the activation of monocytes/macrophages, or using a combination of these two methods. The proposed agent contains as an active substance a factor which boosts phagocytosis activity in the body and in a specific organ, in particular in the brain, or alternatively, a substance that selectively binds to activation markers or adhesion receptors on activated T-lymphocytes or to adhesion receptors on endothelial cells.
A method of N-alkoxyalkylating ureides according to the invention comprises reacting a ureide of structure I with an alkylating agent of structure III in the presence of a basic catalyst in an aprotic reaction medium. The ureide may be a 5,5-disubstituted barbituric acid, or it may be phenytoin, glutethimide, and ethosuximide. The alkylating agent is an ester of a sulfonic acid. The base may be a hydride or amine. A preferred process comprises N-alkoxyalkylating 5,5-diphenyl-barbituric acid with methoxymethyl methanesulfonate in the presence of di-isopropyl ethyl amine and isolating the resultant N,N&#39;-bismethoxymethyl-5,5-diphenyl-barbituric acid. The invention also contemplates the novel compounds N-methoxymethyl-5,5-diphenylbarbituric acid, N-methoxymethyl ethosuximide, and N-methoxymethyl glutethimide, and a method comprising administering them to a patient.
PURPOSE:To reduce the time for inspection and to improve sensitivity by generating antiserum in the living body of an animal with the mycoplasma derived from man as an antigen, refining the antiserum, using the same as an antibody and identifying the mycroplasma of a smear specimen by a direct or indirect fluorescent antibody method. CONSTITUTION:The mycoplasma derived from man is inoculated into a liquid medium added with L-alginin, glucose and phenol red and is cultured to a large amt. at 37 deg.C. The precipitate is gathered by a centrifugal sepn. and is washed by a physiological salt soln. (PBS) and is then made into a 100-times concd. liquid with PBS to prepare the antigen liquid. Such liquid is mixed and emulsified at a prescribed ratio with a Freund&#39;s complete adjuvant and is injected to the subcutaneous muscles of a rabbit at prescribed date intervals. The whole blood is drawn and the serum is separated. An IgG fraction antibody is obtd. by ammonium sulfate salting out. The antibody is diluted with PBS and is added to the specimen to which the mycoplasma to be examined is fixed. The antibody liquid is removed and is cleaned by PBS and thereafter the identification is made by the direct or indirect fluorescent antibody method.
PCT No. PCT/JP90/01612 Sec. 371 Date Aug. 27, 1992 Sec. 102(e) Date Aug. 27, 1992 PCT Filed Dec. 11, 1990 PCT Pub. No. WO91/09611 PCT Pub. Date Jul. 11, 1991.This invention relates to a prophylactic/therapeutic composition comprising a compound of the general formula:   &lt;IMAGE&gt;   (wherein R means an alkanoyl group; a benzoyl group optionally having 1 or more substituent groups selected the group consisting of lower alkyl groups and halogen atoms; a phenylacetyl group; or a cyclohexanecarbonyl group) as an active ingredient, a method for prophylaxis and therapy of fish diseases which comprises administering a food supplemented with said compound to fish, and a fish food containing the same compound. The above composition exhibits beneficial efficacy as a prophylactic/therapeutic agent for fish diseases.
PURPOSE: To provide a process for producing a manicure film which prepares manicure in a film form. CONSTITUTION: A tacky adhesive layer 12 is formed on the surface of release paper 11 subjected to a silicone treatment and a manicure soln. is applied twice thereon and is applied by 30 μ each to form manicure layers 13, 13&#39;. A brightener layer 14 of 30 μ is formed thereon, by which the manicure film is formed. A metallic foil type 15 is adhered to one side at the end of the manicure film and thereafter, the manicure film is covered with a resin film 16 subjected to the silicone treatment. The manicure film is then cut according to the shape and size of the nail.
FIELD: medicinal microbiology. SUBSTANCE: invention relates to strain Vibrio Nag KM N 45 (3792) early unknown serovara 075 used for preparing monovaric diagnostic serum for vibriones identification showing human pathogenicity. Strain is deposited in Collection of Museum living culture of All-Union Research anti-plague Institute &#34;Microbe&#34; at N 45 (3792). Strain shows all features that are typical for Vibrio genus. Strain can be used for serological identification of pathogenic vibriones. EFFECT: improved diagnosis of intestine diseases caused by enteropathogenic vibriones. 1 tbl
PURPOSE:To eliminate erroneous input of medicine order by performing the prescription amount check, the mutual action check, the allergy check, etc., of an inputted medicine order, giving an alarm problem occurs to arouse a doctor&#39;s attention if any problem occurs. CONSTITUTION:The screen display of the past medicine order for a patient, etc., is performed on a CRT device 3 by an information processor 2. Based on this screen display, a keyboard device 1 is operated by a doctor. When either one instruction of the DO, correction, disconnection instructions of the medical order is inputted, this instruction contents is fetched, the prescription amount check, the mutual action check and allergy check of this medicine order are performed. If a problem occurs, an alarm is given and a doctor&#39;s attention is aroused. If no problem occurs, this medicine order is transmitted to a medicine part, etc.
The invention discloses a chicken Marek&#39;s disease (MD) Meq gene deleted vaccine strain, a construction method thereof, and an application thereof. The chicken Marek&#39;s disease rMS delta Meq gene deleted vaccine strain has a microbe reservation number of CGMCC No. 4612. According to the invention, on a basis of a parent strain which is MDV MS strain, a 468bp base sequence on a front part of a main oncogene is deleted thorough two times of homologous recombination, such that the chicken Marek&#39;s disease Meq gene deleted vaccine strain is obtained. The invention also relates to the application of the gene deleted vaccine strain in preparation of medicine used for controlling chicken Marek&#39;s disease, and in detection and disgnosis methods used for distinguishing a vaccine strain and a chicken Marek&#39;s disease wild strain, wherein the methods are designed aiming at the deleted gene sequence of the gene deleted strain. The gene deleted vaccine strain provided by the invention has good safety and good immuno-protection effect upon chicken Marek&#39;s diseases. The vaccine strain can be used for preparing monovalent vaccines or combined vaccines used for controlling chicken Marek&#39;s disease.
PURPOSE: To provide pharmaceuticals which consist of specific phenyl pyrazoles and phenyl isothiazoles as effective components and are used to treat an inflammatory intestinal disease or to prevent the recurrence thereof and to lessen the danger of a cancer. CONSTITUTION: The pharmaceuticals consist of the compd. of the formula [X is S, N, methyl substd. N; R is H, amino, a 1 to 3C alkylamino, OH; R&lt;1&gt; is OH, OM (M is nontoxic cation); R&lt;2&gt; , R&lt;3&gt; are H, a halo, a 1 to 3C alkyl, trifluoromethyl, a 1 to 3C alkoxy] as the effective components and are used as the medicine for treating the inflammatory intestinal disease and for prevention of the recurrence thereof. The pharmaceuticals contg. the compd. of the formula I in particular are for topical administration, such as suppository and enema, suitable for rectal administration. The compd. of the formula I is, for example, sodium 3-(3-trifluoromethylphenyl)-4-aminopyrazole-5-carboxylate, tetraethylammonium 3-(3-chloro-4-methylphenyl)isothiazole-5-carboxylate, etc. The medicine particularly prevents the colorectal cancer and prevents the recurrence thereof.
The invention discloses a kind of Chinese medicine preparation for the treatment of senile hypothyroidism.Senile hypothyroidism &#34; hypothyroidism &#34; belongs to the traditional Chinese medical science &#34; asthenia &#34; category, and motherland&#39;s medical science thinks that primary disease is how not enough by natural endowment, loses the day after tomorrow and supports, or internal injury of being overworked for a very long period, and prolonged illness imbalance causes kidney qi, deficiency of spleen-QI, then caused by deficiency of spleen-YANG and kidneyYANG.The present invention selects to have nourishing YIN and invigorating YANG, kidney and spleen invigorating, the Chinese medicine Rhizoma Tupistrae Chinensis of blood circulation promoting and blood stasis dispelling, Rhizoma Polygonati Cirrhifolii, Radix Tylophorae arenicolae, Herba Silenes conoideae, Lignum corni macrophyllae, Fructus Pandani tectorii, Pleurotus citrinopileatus Sing (Pleurotus ulmarius (Bull. Ex Fr.) Quel.), Flos Caraganae intermediae, Folium Ilicis Cornutae, Abacopteris multilineata(Wall.) Ching (Pronephrium multilineatum (Wall.) ching, decocting becomes decoction, through clinical trial, total effective rate reaches 93.3%, curative effect highly significant.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for extracting an effective component in an object to be treated by extraction with ethanol, which method is free from influence of water upon concentrating the effective component.  &lt;P&gt;SOLUTION: The extraction method is comprised of a drying step, an extraction step and a concentration step. An object to be treated by extraction with ethanol is dried in the drying step so as to reduce its moisture to 1.0% or less, whereby the object is made virtually free of water and therefore ethanol concentration is not remarkably reduced by the water contained in the object upon extracting the effective component with ethanol. Additionally by using ethanol having a concentration of 99.5% or higher in the extraction step, the ethanol solution that has extracted the effective component is kept virtually free of water. Thereby, the effective component can be easily obtained without causing the effective component dissolved in ethanol to precipitate even when ethanol is being separated from the ethanol solution comprising the effective component in the subsequent concentration step.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
The invention provides taxol freeze dried micro emulsion used for injection and a preparation method thereof. The freeze dried micro emulsion comprises taxol in effective dosage as the drug and pharmaceutic adjuvant such as oil phase, an emulsifier, an assistant emulsifier, a pH regulator, isotonic regulator and a freeze dried protective agent. The preparation method comprises the following steps: weighing the emulsifier in the amount according to the prescription, after evenly stirring the assistant emulsifier and oil for injection, adding the taxol into the mixed liquor and stirring for complete dissolution, then adding water for injection, completely stirring, obtaining taxol micro emulsion after regulating the pH value, further adding the freeze dried protective agent, and obtaining the freeze dried micro emulsion after vacuum freeze drying. Micro emulsion can be rapidly recovered by using physiologically compatible solution such as normal saline, glucose solution or Ringer&#39;s solution for dilution before use. The freeze dried micro emulsion and the preparation method are characterized in that through the further freeze drying technique to the taxol micro emulsion, the stability and the efficacy of the taxol are obviously enhanced, and the toxic and side effects are greatly reduced; especially, the freeze-drying method realizes very good protection function to the micro emulsion and avoids effusion of drug, thereby breaking through a new prospect for the establishment of stable dose pattern of a taxol micro emulsion drug loaded system and long-term preservation thereof. The preparation method for the freeze dried micro emulsion has the advantages of simple preparation technique, no organic solvent and low cost, therefore, the invention is suitable for industrialized mass production.
A computer implemented method and system is for training a subject&#39;s articulation. The system will receive, access and analyze the speech audio and video data of the subject. The data will be compared to standard speech audio and video data to calculate the deviation of the articulatory parameters between the recorded data of the subject and the standard data. The system will then deconstruct the speech unit and separately play the standard tongue movements, lip movements, jaw movements, and airstream generation. The system will then enable a gradual time converging of the initial separately played standard tongue movements, jaw movements, lip movements and airstream generation in response to a magnitude of the at least articulatory parameter deviation decreasing. Similarly, the system will adapt the display speed and the number of repetitions of these movements to optimize the articulation training.
PURPOSE:To obtain a photographic processing agent capable of being easily transported and stored, appropriate for an automatic liq. preparation replenishing mechanism and with the environmental pollution reduced by mixing &gt;=2 kinds of the powdery chemicals to be used as a photographic processing agent and granulating the mixture with a specified powdery chemical. CONSTITUTION:Two or more kinds of the powdery chemicals to be used as a photographic processing agent are mixed, the mixture is granulated with a powdery chemical so that the water content including water of crystallization is controlled to &lt;=10% of the total weight of the granulated material. In this case, an ordinary granulation aid is preferably used, and the water content including water of crystallization is controlled to &lt;=10%, preferably to &lt;=5% or more preferably to &lt;=1% when water is used. Besides, water, alkali or acid- soluble polymers can be used. Consequently, the transportation and storage are facilitated, the agent is highly soluble and appropriate for a miniaturized automatic liq. preparation replenishing mechanism, the grain strength is increased, the powder is not released due to disintegration, the powdery agent is not left in the package, and further environmental pollution is reduced.
PURPOSE:To obtain the titled troche containing indomethacin as an active component. CONSTITUTION:An effective troche for the remedy of pharyngeal pain and having low side effect can be produced by using 3-10mg of indomethacin fine powder as an active component per 1 tablet and uniformly mixing the component with conventional excipient, binder, sweetener, flavor and various other proper additives. A sufficient remedying effect cannot be attained by the use of &lt;3mg of indomethacin per 1 tablet. When the content exceeds 10mg, the side effect is liable to develop and strong bitter taste is imparted to the tablet to inhibit the practical use of the tablet. The content of indomethacin is preferably 5mg. EFFECT:Since a troche enables the direct action of indomethacin to the diseases part of pharynx, a remedying effect can be achieved at a relatively low dose compared with other drug forms such as tablet, capsule, suppository, etc.
Systems and methods are provided for predicting rare events, such as hospitalization events. Data related to health and/or healthcare may be compiled from a number of sources and used to construct a predictive model. The predictive model employ Principal Component Analysis (PCA) and Partial Least Squares (PLS). The data may be arranged in a timeline, and formatted in such a way as to provide discrete temporal “batches”. This arrangement may facilitate the PCA and PLS decomposition of the data into predictive models. These models may then be applied to an individual&#39;s data, to create a prediction of healthcare related events.
Ovarian cancer, notably high-grade serous ovarian cancer (HGSC), the principal cause of death from gynecological malignancies in the world, has not significantly benefited from recent progress in cancer immunotherapy. While HGSC infiltration by lymphocytes correlates with superior survival, the nature of antigens that can elicit anti-HGSC immune responses is unknown. Novel tumor-specific antigens (TSAs) shared by a large proportion of ovarian tumors are described herein. Most of the TSAs (&gt;80%) described herein derives from aberrantly expressed unmutated genomic sequences, such as intronic and intergenic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells and vaccines derived from these TSAs are described. The use of the TSAs, nucleic acids, compositions, cells and vaccines for the treatment of ovarian cancer is also described.
1,210,022. Skin-treating preparation. PREPHAR PROSPECTION DE RECHERCHES PHARMACEUTIQUES S.A. 16 Sept., 1968 [14 Sept., 1967], No. 43869/68. Heading A5B. A material named &#34;natural glucidamines&#34; and containing: partially depolymerised glycoproteins containing hexoses, hexosamines and short chain proteins; depolymerised polysaccharides consisting of hexosamines and uronic acids and sulphonated polysaccharides containing -SO 3 H groups, partially acetylated hexosamines and uronic acids, is obtained by extracting animal hide, skin or other organs rich in connective tissue by extraction with acetone, dissolving the residue in boiling aqueous NaOH, cooling and precipitating with acetone after addition of acetic acid, dissolving the precipitate in water, digesting with papain and precipitating the product with acetone after addition of acetic acid. The product may be put up into topically applicable forms, e.g., creams and used for the treatment of cellulitis, epidermic regeneration, treatment of wrinkles &amp;c.
PURPOSE: To produce fine particles uniform in particle size distribution by passing a soln. or a suspension and a soln. of a different nature through respective pipelines and colliding the solns. with each other in a collision chamber. CONSTITUTION: The respective aq. soln. and org. solvent soln. in a feed tanks 2 with a jacket kept at a constant temp. by a heating and cooling device 1 are mixed by pumps 3 through a pneumatic three-way valve 4 and a check valve 5. At this time, the excess solns. are returned to the feed tanks 2 through a circulating line 6, and the solns. are stably supplied. The liq. mixture is sent to a high-pressure pump 10 after adjusting the supply amount by a needle valve 9. The liq. mixture pressurized by the pump 10 is sent to a collision chamber 12 through a filter 11 and separated into two liqs. in the chamber 12. The two liqs. are collided with a flat part in a flow passage or with each other at a mutual pressure of &gt;=300kg/cm&lt;2&gt; , and a fine particle is produced. The obtained particle-contg. liq. is cooled by a cooler 13 and recovered.